within Pharmacolibrary.Drugs.ATC.C;

model C10AA08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.51,
    Cl             = 0.00033166666666666663,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.133,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0235,
    Tlag           = 12.78,            
    Vdp             = 0.083,
    k12             = 22.8,
    k21             = 22.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AA08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pitavastatin is a synthetic lipid-lowering agent of the statin class used to treat hypercholesterolemia and mixed dyslipidemia. It selectively inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis. Pitavastatin is currently approved in many countries for the treatment of elevated cholesterol to reduce cardiovascular risk.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of pitavastatin following single 2 mg oral dose in healthy adult males.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544050-00002&quot;>10.2165/00003088-200544050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15871634/&quot;>https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Saito, Y (2011). Pitavastatin: an overview. <i>Atherosclerosis. Supplements</i> 12(3) 271–276. DOI:<a href=&quot;https://doi.org/10.1016/S1567-5688(11)70886-8&quot;>10.1016/S1567-5688(11)70886-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22152281/&quot;>https://pubmed.ncbi.nlm.nih.gov/22152281</a></p></li><li><p>Choi, CI, et al., &amp; Lee, SY (2012). Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 42(5) 496–501. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2011.632030&quot;>10.3109/00498254.2011.632030</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22077103/&quot;>https://pubmed.ncbi.nlm.nih.gov/22077103</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AA08;
